Comprehensive Genomic Profiling

The AJMC® Comprehensive Genomic Profiling compendium is a comprehensive resource for clinical news and expert insights for the next-generation sequencing approach to assess genes for the purpose of therapy guidance.

Latest News

Health care tech.
ICYMI: Highlights From the 2022 American Academy of Dermatology Meeting

December 17th 2022

This American Academy of Dermatology (AAD) Annual Meeting covered a breakthrough therapy for the management of vitiligo, clinical and epidemiological differences of certain dermatologic diseases, and the role of dietary triggers on patient outcomes.

Image of a person's DNA
WGS Feasible, Valuable in Metastatic Cancer Management

July 19th 2022

woman getting results
Survey Provides Insight Into Patient Experiences Receiving Comprehensive Tumor Genomic Profiling Results

July 16th 2022

microscope.
Method of Tissue Acquisition May Determine Success of Gene Sequencing in Lung Cancer

July 7th 2022

FOENIX Update: A New Era in Cholangiocarcinoma Precision Medicine
FOENIX Update: A New Era in Cholangiocarcinoma Precision Medicine

July 1st 2022

Advancing Precision Medicine Through Comprehensive Genomic Profiling (CGP)

Payer and clinician insight regarding the integration of comprehensive genomic profiling into routine clinical practice to help oncologists make more informed treatment decisions for patients with cancer.

Bruce Feinberg.

More News

Megan Olsen, MPH
February 4th 2022

Avalere Analyst Lists the Challenges Medicaid Plans Must Overcome When Deciding to Use Cell and Gene Therapies

Skylar Jeremias
Megan Olsen, MPH, principal at Avalere, explores the challenges that arise for Medicaid plans when providers choose to prescribe a cell or gene therapy.
gene DNA graphic
February 2nd 2022

Has the Time Arrived to Incorporate Genetic Testing Into Health Care?

Gianna Melillo
The rise in popularity of genetic testing brings along a myriad of challenges ranging from concerns on data privacy to insurance coverage, but, when utilized correctly, it could mark a step forward for significant advancements in individual and population health.
Megan Olsen
January 28th 2022

Avalere Analyst Describes How COVID-19 Has Impacted the Cell and Gene Space

Skylar Jeremias
Megan Olsen, MPH, principal at Avalere, provides a comprehensive overlook into the many ways that the COVID-19 pandemic has impacted the cell and gene therapy space.
DNA.
January 24th 2022

Genomic Profiling Uncovers Mutations More Enriched in Early-Onset Colorectal Cancer

Matthew Gavidia
Findings presented at the 2022 ASCO Gastrointestinal Cancers Symposium showed no significant differences in tissue and plasma genomic profiles of patients with early-onset and late-onset colorectal cancer, but a greater enrichment of the BRCA1 and PTEN mutations were noted in the tissue of those with early-onset disease.
Researchers examining DNA.
January 20th 2022

Common Mutations in Chinese Patients With NSCLC Linked With Treatment Outcomes, Disease Severity

Matthew Gavidia
The frequency of several mutations that inhibit response to tyrosine kinase inhibitors and tend to lead to increased disease severity was elevated in Chinese patients with non-small cell lung cancer.
doctor holding a model of lungs and a file folder
January 17th 2022

Intensified Analysis of CGP Results Likely Necessary Among Some Patients With NSCLC

Skylar Jeremias
Prior to receiving therapy for non–small cell lung cancer (NSCLC), some patients' results may require analysis beyond comprehensive genomic profiling (CGP).
Looking at DNA.
January 14th 2022

Genomic Profiling for NSCLC Improves Survival Outcomes With Modest Budget Impact

Matthew Gavidia
An increase in the use of comprehensive genomic profiling among patients with advanced non–small cell lung cancer (NSCLC) was associated with additional life-years gained and a low-cost budget impact.
DNA in a test tube
January 10th 2022

How Does CGP Testing Align With Recommendations, Impact Budgets?

Skylar Jeremias
Posters from the Academy of Managed Care Pharmacy Nexus 2021 meeting detailed how coverage of genetic testing aligns with current guidelines as well as the potential budget impact of expanding access to comprehensive genomic profiling (CGP).
Doctor on a computer.
January 6th 2022

Molecular Profiling Identifies Potential Prognostic Biomarker for Treatment Response in HNSCC

Matthew Gavidia
Human papillomavirus surrogate marker p16 was identified as a potential prognostic biomarker for standard-of-care immune checkpoint blockade therapy response in non-oropharyngeal head and neck squamous cell carcinoma.
Megan Olsen, MPH
December 29th 2021

Avalere Analyst Weighs In on How Value Assessments Will Influence Gene and Cell Therapy Pricing

Megan Olsen, MPH, principal at Avalere, discusses the role that value assessments are expected to play in the future pricing of gene and cell therapies.
model of DNA and a magnifying glass sitting on top of a map of the world
December 22nd 2021

Top 5 Most-Read Comprehensive Genomic Profiling Articles of 2021

Skylar Jeremias
The top 5 most-read comprehensive genomic profiling articles of 2021 on AJMC.com largely focused on the use of liquid biopsy and how biomarkers can offer providers new ways to help predict treatment-related outcomes and identify therapeutic targets.
Genetics, Epigenetics, and Cancer: What Data Are We Missing?
December 19th 2021

Genetics, Epigenetics, and Cancer: What Data Are We Missing?

Mary Caffrey
During the discussion of disparities in cancer care, one panelist explained that the National Institutes of Health definition of precision medicine is broader than most people realize.
Avalere Analyst on How Payers Make Cell, Gene Therapy Decisions With Limited Data
December 15th 2021

Avalere Analyst on How Payers Make Cell, Gene Therapy Decisions With Limited Data

Megan Olsen, MPH, principal at Avalere, discusses how the impact of small patient populations and other limitations may influence payer conversations about gene and cell therapies.
red blood cells flowing in stream
December 13th 2021

Review: NGS Reveals Migration Patterns of B Cells Across Blood-Brain Barrier for MS

Skylar Jeremias
Next-generation sequencing (NGS) may be a helpful tool for establishing how B cells migrate and maturate across the blood-brain barrier in multiple sclerosis (MS), potentially providing better insight into the pathophysiologic mechanisms involved in neuro-inflammation.
Scientist extracting liquid.
December 10th 2021

Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

Matthew Gavidia
Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping was found to be noninferior to standard-of-care tissue-based genotyping for detection of guideline-recommended biomarkers and therapeutic outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC).
doctor wearing latex gloves holding a vial containing DNA
December 8th 2021

FDA Approves First CGP Test as Companion Diagnostic for BRAF Inhibitor Therapies for Melanoma

Skylar Jeremias
The FDA approved FoundationOneCDx as the first companion diagnostic for current and future BRAF inhibitor therapeutics used to treat melanoma, including both monotherapies and combination therapies.
magnifying class being held over a portion of DNA
December 2nd 2021

Integrating Molecular Profiling of Adrenocortical Carcinoma Into Clinical Practice

Deanna Ferreri, PhD
Processes used to identify and understand genetic markers detailing the prognosis and responsiveness to therapy in adrenocortical carcinoma (ACC) face a number of implementation barriers, limiting the potential for individualized ACC management.
DNA.
December 2nd 2021

Genomic Profiling Identifies 3 NSCLC Subtypes Predictive of Adjuvant Therapy Outcomes

Matthew Gavidia
Next-generation sequencing uncovered 3 subtypes of epidermal growth factor receptor–mutant stage 2 and 3 non–small cell lung cancer (NSCLC) that predicted patient outcomes to adjuvant therapy.
Funmi Olopade, MD
November 29th 2021

Dr Funmi Olopade Explains the Importance of Transgender Women in Breast Cancer Research

Hayden E. Klein
Funmi Olopade, MD, FACP, professor of medicine and human genetics and founding director of the Center for Clinical Cancer Genetics and Global Health at the University of Chicago Medical Center, explains how transgender women are included in breast cancer research and emphasizes why it is important to include all women.
model of DNA in a test tube
November 27th 2021

NGS, Prediction Tools Show Similarities Between Metastatic Breast Cancer, Other Advanced Cancers

Skylar Jeremias
Next-generation sequencing (NGS) and the use of prediction tools in 2 patients with a rare form of metastatic breast cancer revealed mutations in malignant phyllodes tumors that are often detected in other advanced cancers, providing insight into potential therapeutic targets for these patients.
George Van Antwerp, Deloitte
November 24th 2021

George Van Antwerp: Specialty Drugs Rely on Personalization for Optimal Outcomes

The high cost of specialty drugs makes it important to use companion diagnostics and other tests to make sure the drug is going to the right patient, said George Van Antwerp, MBA, managing director, Deloitte Consulting.
Researchers Report Promising Strategy to Develop Personalized Therapy for Neuroblastoma
November 18th 2021

Researchers Report Promising Strategy to Develop Personalized Therapy for Neuroblastoma

Deanna Ferreri, PhD
Using cell cultures from pediatric patients with neuroblastoma, researchers performed drug-response testing and investigated correlations between copy number and cytotoxicity of drug treatment.
Pathologists Discuss Actionable Mutations and Testing in Metastatic Breast Cancer
November 14th 2021

Pathologists Discuss Actionable Mutations and Testing in Metastatic Breast Cancer

Tony Hagen
Genetic profiling in recurrent and advanced breast cancer can yield actionable, smoking-gun biomarkers, Stanford Cancer Institute pathologists explained at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors.
genes
November 12th 2021

Survey of Australian Oncologists Finds Room for Increasing Their Confidence With CGP

Allison Inserro
A recent survey of oncologists in Australia showed that while most are integrating comprehensive genomic profiling (CGP) into their practice, they lack a high level of confidence to communicate findings and to adjust patient treatment accordingly.
DNA sample testing.
November 12th 2021

Recommendations, Insights on Use of Comprehensive Genomic Profiling in Oncology

Matthew Gavidia
A discussion at the National Comprehensive Cancer Network 2021 Virtual Congress: Biomarkers in Solid Tumors addressed the advantages and considerations for broad and targeted genomic profiling in oncology.
Patient in the hospital.
November 4th 2021

Study Finds Predictive Biomarkers for Chemo-Radiotherapy Toxicity, Efficacy in NSCLC

Matthew Gavidia
Several biomarkers identified by comprehensive genomic profiling were found to predict efficacy and toxicity of chemo-radiotherapy in patients with non–small cell lung cancer (NSCLC), with progression-free survival and overall survival outcomes associated with some of the identified genes.
DNA in a vial surrounded by red blood cells
November 2nd 2021

Genetic Biomarker Test Calculates Recurrence, Survival Outcomes for Men With Prostate Cancer

Skylar Jeremias
A genetic biomarker test for patients with aggressive prostate cancer was found to identify which patients are more likely to respond to radiation and hormone treatments or develop metastases, allowing providers to personalize therapy regimens for high-risk patients.
doctor looking at a digital screen containing illegible health information
October 28th 2021

Liquid Biopsy Blood Biomarker Possible Predictor of Tumor Recurrence, Cost Savings

Skylar Jeremias
A study concluded that use of a multigene liquid biopsy blood biomarker for diagnosis of neuroendocrine tumors was over 94% effective at predicting tumor recurrence compared with other commonly used biomarker, Chromogranin A.
DNA in a physician's hand.
October 27th 2021

Genomic Profiling Linked With Improved Patient Outcomes in Advanced NSCLC

Matthew Gavidia
Use of comprehensive genomic profiling in patients with advanced non–small cell lung cancer (NSCLC) was linked with significant improvements in progression-free survival and overall survival.
Image depicting genes and dna
October 23rd 2021

Consider Conducting Genomic Evaluations Earlier When Advanced Cancer Is Involved, Study Suggests

AJMC Staff
Molecular profiling is more often used after standard cancer treatments have failed; a recent study suggests that it could effectively guide first-line treatment, especially for cancers with a poor prognosis.
<1234>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo